April 24, 2025

FDA Warns of Topical Finasteride Risks

The FDA has issued a safety alert on compounded topical finasteride products, citing adverse events and emphasizing the lack of regulatory approval or safety evaluation.

Conexiant

April 23, 2025

Long-Term EEG Monitoring Now Authorized in the United States

The FDA has authorized Minder, the first implantable continuous electroencephalogram monitor, offering long-term brain activity tracking for improved epilepsy management, available in the U.S.

Conexiant

April 23, 2025

FDA Targets Petroleum-Based Dyes in Food Supply

The FDA and HHS announced plans to eliminate petroleum-based synthetic food dyes, citing potential health risks and aligning with global safety standards.

Conexiant

April 21, 2025

New Prescription App Reduces Migraine Days

The FDA has authorized CT-132, the first prescription digital therapeutic for episodic migraine prevention, based on clinical trial data showing reduced monthly migraine days.

Conexiant

April 18, 2025

Intranasal Diazepam Gains Expanded Approval for Pediatric Patients

“Approval of an immediate-use intranasal diazepam treatment that can be given at any time—even while a child is actively seizing—in this young age group is an important advance for the epilepsy community.”

Conexiant

April 10, 2025

September Deadline for Autism Etiology Findings

Federal initiative aims to pinpoint causes of rising autism rates by September, as HHS Secretary Kennedy launches global research effort.

Reuters

April 07, 2025

Cannabis for Pain: ACP Issues Best Practices

New guidelines from the American College of Physicians address the limited benefits and potential harms of cannabis and cannabinoids for chronic noncancer pain management.

Conexiant

April 02, 2025

Unequal Access Worsens Opioid Crisis for Black Patients

Despite rising opioid overdose rates among Black patients, systemic barriers and unequal access to treatment continue to hinder recovery efforts and worsen outcomes.

KFF Health News

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant